PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.85%
Revenue growth above 1.5x AVGO's 1.38%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
17.82%
Gross profit growth above 1.5x AVGO's 3.98%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
23.29%
EBIT growth 50-75% of AVGO's 31.59%. Martin Whitman would suspect suboptimal resource allocation.
31.03%
Operating income growth similar to AVGO's 31.59%. Walter Schloss would assume both share comparable operational structures.
-1.96%
Negative net income growth while AVGO stands at 22.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2.65%
Negative EPS growth while AVGO is at 25.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.03%
Negative diluted EPS growth while AVGO is at 16.67%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share reduction more than 1.5x AVGO's 0.50%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.22%
Diluted share reduction more than 1.5x AVGO's 1.20%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
0.13%
Maintaining or increasing dividends while AVGO cut them. John Neff might see a strong edge in shareholder returns.
-16.10%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-18.43%
Negative FCF growth while AVGO is at 0.26%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
31.77%
10Y revenue/share CAGR under 50% of AVGO's 527.66%. Michael Burry would suspect a lasting competitive disadvantage.
23.77%
5Y revenue/share CAGR under 50% of AVGO's 120.62%. Michael Burry would suspect a significant competitive gap or product weakness.
-0.08%
Negative 3Y CAGR while AVGO stands at 31.72%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
41.36%
10Y OCF/share CAGR under 50% of AVGO's 1275.71%. Michael Burry would worry about a persistent underperformance in cash creation.
13.88%
Below 50% of AVGO's 253.00%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-9.71%
Negative 3Y OCF/share CAGR while AVGO stands at 93.81%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
103.37%
Below 50% of AVGO's 231.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
88.52%
5Y net income/share CAGR similar to AVGO's 88.50%. Walter Schloss might see both on parallel mid-term trajectories.
13.44%
Below 50% of AVGO's 44.46%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
7.90%
Below 50% of AVGO's 949.30%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-7.15%
Negative 5Y equity/share growth while AVGO is at 262.27%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-18.37%
Negative 3Y equity/share growth while AVGO is at 20.29%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
644.90%
Dividend/share CAGR of 644.90% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
163.60%
Below 50% of AVGO's 776.34%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
79.57%
Below 50% of AVGO's 279.34%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
18.37%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-3.00%
Inventory is declining while AVGO stands at 13.43%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.37%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.79%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
0.01%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
1.85%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
1.50%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.